We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder.
- Authors
Azar, Pouya; Schneiderman, Hannah; Barron, Henry; Wong, James S. H.; Meyer, Maximilian; Newman-Azar, Dayyon; Narimani, Matin; Ignaszewski, Martha J.; Mathew, Nickie; Mullen, Rodney; Krausz, Reinhard M.; Maharaj, Anil R.
- Abstract
Background: Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier. Case Presentation: We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms. Conclusions: This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
- Subjects
OPIOID abuse; BUPRENORPHINE; DRUG withdrawal symptoms; BURDEN of care
- Publication
Addiction Science & Clinical Practice, 2024, Vol 19, Issue 1, p1
- ISSN
1940-0632
- Publication type
Case Study
- DOI
10.1186/s13722-024-00479-1